News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PolyMedix Inc. (PYMX.OB) Receives USAN Approval for Generic Name of Brilacidin for PMX-30063


6/13/2012 9:42:49 AM

RADNOR, Pa., June 12, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care conditions, today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "brilacidin" (pronounced bri-la-ci-din) for PMX-30063, a first-in-class defensin mimetic antibiotic. PolyMedix recently announced positive results from a Phase 2 clinical study with brilacidin as an intravenous treatment in patients with acute bacterial skin and skin structure Staph aureus infections.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES